OvuSense logo

OvuSense - designed by clinical experts

Click on the tabs below to explore the clinical background to OvuSense

OvuSense was developed with the help of specialist clinicians and is specifically designed for the 70% of women who are unsure of when they ovulate, or who ovulate at a different time in their cycle from the accepted 'middle of the month norm'. You may be one of the many that unsure of whether or not you ovulate and when it happens, and that’s where OvuSense can help.

OvuSense has two parts: an App and a Sensor. The OvuSense App allows you to sign-up your clinician, partner, family and friends so you can share your charts. The charts can be viewed by any shared user on any internet accessible iOS or Android device.

Clinically proven: OvuSense is the most advanced cycle monitoring system you can buy - clinically proven in over 50,000 cycles of use.

Real time 24 hour advance ovulation prediction: Unlike any other monitor, OvuSense provides a day's advance notice of when you are going to ovulate in real time along with your 4 day ovulation window - proven in clinical analysis to be correct 96% of the time.

8 day fertile window: In addition, at the start of each cycle OvuSense provides a full 8 day fertile window - these features help you take back control of your planning for pregnancy.

Fully certified: OvuSense is a fully regulated medical device and complies with all the necessary certifications for the countries in which it is available - CE mark in Europe, FDA 510(k) in USA, CMDCAS in Canada, TGA in Australia.

'Core temperature' technology: The rest of this page explains the clinical case for OvuSense's 99% accurate patented technology, and why other products produce an incorrect result in at least one in every five cycles.

How does it work?

OvuSense is different from anything else you may have heard of, or used previously to monitor your fertility. That's because it measures core body temperature using a specially designed vaginal sensor proven in over 50,000 cycles of use. The vaginal sensor is used overnight only, and data are downloaded to the dedicated OvuSense App each morning. OvuSense provides live updates predicting ovulation up to 24 hours in advance using your current cycle data, then confirming the date of ovulation, all in one device.

What are the benefits?

By providing core temperature data in real time, throughout each cycle, OvuSense solves the issues variable ovulation causes with monitoring fertility. Even if you have completely regular ovulation, the live prediction with a positive predictive value of 96% [a] and the 99% accurate ovulation confirmation [b] improve your chances of successful conception. OvuSense effectively combines the benefits of OPKs with the benefits of BBT measurement - with the convenience of monitoring in a single device. However, it is more accurate than both methods, going one step further by enabling clinical monitoring in conjunction with the tests offered by your doctor. OvuSense has been clinically proven in 5 key peer reviewed publications [c], [1], [2] which reported on 2 clinical trials. The OvuSense technology also has 8 granted patents [3]

What are the drawbacks?

OvuSense provides more accurate results by using a vaginal sensor. Some may find this less convenient than tracking using an external device, but many users report finding the routine of using OvuSense takes the hassle and guesswork out of understanding their cycles. The comfort and ease of use of the sensor was also published clinically [4].

[a] The positive predictive value measures how many of the predicted ovulations OvuSense gets right.

[b] The accuracy measures how many positive and absent ovulations OvuSense confirms correctly.

[c] Note: 4 of the OvuSense publications were clinical posters shown at the annual meetings of the two largest clinical societies for reproductive medicine: ESHRE and ASRM. Poster publications are reviewed by a committee of peers for both societies and only allowed to be presented if deemed of sufficient scientific merit and robustness. They are then published as part of the proceedings of the meetings in the official society journals 'Human Reproduction' and 'Fertility and Sterility', respectively. As is the norm with the development of medical devices, the OvuSense trials were sponsored by the company but the primary authors of the posters are independent clinicians.

[1] The key publication outlining prediction of ovulation was shown at the 2014 ESHRE meeting: Papaioannou S, Delkos D, Pardey J (2014)

[2] The claims for accuracy are based on the data set shown in [1], originally published at the 2013 ASRM meeting as a quality index: Papaioannou S, Aslam M (2013)

[3] US Patents: US8684944, US8496597, US9155522, US9155523, US20190110692; European patents: EP1485690, EP2061380; Chinese patent: CN1650154

[4] The comfort and ease of use of OvuSense were published in the Journal of Obstetrics and Gynecology in 2013, and this survey is repeated annually with our customers with continuous as good or better results: Papaioannou S, Aslam M (2013)

Clinical studies show that around 25% of the total childbearing population suffer from one or more ovulatory issues, which rises to an estimated 70% of the population trying to conceive after 6 months.

So if you've been trying for more than 6 months without success, there's a high chance you have an issue with ovulation. The good news is the issues are treatable, and the treatment can often solve the problem with conception.

Ovulatory issues are broadly hormonal reasons which might cause you to ovulate irregularly or simply at a different time in the cycle than expected. Traditional thinking about predicting ovulation is based on the assumption that ovulation consistently occurs 14 days before the onset of the next period - so in the 'middle of your cycle' if you have a 28 day cycle. In fact, we now know that only a small percentage of women ovulate exactly 14 days before the onset of their period. Baird et al. (1995) - study size 221, Lenton et al. (1984 a & b) - study sizes 327 and 293 cycles, respectively.

Ovulatory issues can contribute to this confusion. The most common ovulatory issues are described below:

Polycystic Ovarian Syndrome (PCOS) is a very common condition that affects up to one in 10 women of child bearing age. It is sometimes but not always accompanied by Polycystic Ovaries (PCO) – which is believed to affect around 20% of women. With PCO, many (poly) follicles (cysts) develop within the ovary without necessarily rupturing. If a follicle doesn’t rupture then no ovulation takes place.

Ovarian reserve (OR) is a measure of the quantity and quality of the follicles left in the ovary at any given time. The follicle is a fluid filled sac within which an egg (oocyte) develops. So Ovarian Reserve determines how well an ovary can produce eggs that are can be fertilized, resulting in a healthy and successful pregnancy.

Diminished Ovarian Reserve (DOR) is known under a number terms including Poor/ Decreased/ Declining/ Low/ Impaired Ovarian Reserve, or Premature Ovarian Ageing. As a woman ages the number of follicles she has declines from approximately 2 million at birth, to 400,000 at puberty to 1,000 at menopause. The speed at which the follicle number declines varies from woman to woman, and some genetic and autoimmune conditions can accelerate the process.

A number of studies have reported the high levels of PCO and the subset of PCOS, and potential reasons for poor detection rates:

  • 21-23% of the female population has PCO.
    Polson et al.(1988) – study size 257; Clayton et al. (1992) – study size 190; Farquhar et al. (1994) – study size 183
  • ~10% of the female population has PCOS.
    March et al. (2010) – study size 728, Sirmans et al. (2013) – quotes March and 3 other studies with 820, 929 and 392 women
  • Around half of women with PCO go undiagnosed.
    Kousta et al. (1999) – study size 278
  • PCO is found in 44% of women with unexplained infertility.
    Kousta et al. (1999)
  • 30% of women with PCOS have normal menses (and hence no apparent cyclical evidence of irregular ovulation).
    Balen A et al. (1995) – study size 1,741
  • Elevated levels of LH have been reported with potential greater prevalence in non-obese PCOS patients.
    Dale PO et al. (1992) – study size not available, Ciotta L et al. (1999) – study size 16.

Having no evident external manifestation of PCOS, non-obese patients are less likely to be suspected of having PCOS, and therefore have a lower chance of detection. Clinical observation.

Diminished Ovarian Reserve (DOR). The definition of whether a woman is 'suffering' from DOR is broad, because it is largely a progressive effect of ageing. Centers for Disease Control (2007, 2011) clinic statistics for the US show that the population entering into infertility treatment with DOR grew from 10% to 30% during the period 2007 to 2011 (the most recently available year).

From the clinical study, Wallace and Kelsey (2010) – 8 studies with total 325 ovaries estimates that 95% of women by the age of 30 years only have 12% of their maximum pre-birth ovarian reserve remaining, and that by the age of 40 years only 3% of the reserve remains.

As the average age for childbearing rises, so will the percentage of women that are trying to conceive with DOR. It’s therefore reasonable to assume that the population of women with DOR after trying to conceive for 12 months is currently around 10% and growing. DOR generally results in lower levels of reproductive hormones and hence most ovulation testing is impaired, both home based LH testing, and laboratory testing.

The statistics above probably also explain the extremely high percentage of women who have 'unexplained infertility' – i.e. no diagnosis of the cause of their inability to conceive throughout the patient pathway:

  • 30% after first diagnosis ASRM (2006)
  • 43% on entering IVF treatment, i.e. after last diagnosis HFEA (2013)

We now know from other literature only a small percentage of women ovulate exactly 14 days before the onset of menses. Baird et al. (1995) - study size 221, Lenton et al. (1984 a & b) - study sizes 327 and 293 cycles, respectively. This being the case even for women who usually experience a 28 day cycle length. In addition, as Wilcox et al. (2000) – study size 221 demonstrated, the fertile window falls entirely between cycle days 10 and 17 in only about 30% of women. Most women reach their fertile window earlier and some much later. This 'norm' continues to become less common as couples attempt to conceive later in life.

Meet the fertility experts

Dr Irfana Koita
Consultant at IVF Matters
Kate Davies
Fertility Nurse and Coach at Your Fertility Journey
Carys Morgan
Acupuncturist, motivational writer and speaker
Dr Nicola Harrison
Private General Practitioner
Amy Medling
Certified Health Coach and founder of PCOS Diva
Angela Heap
Fertility Nutritionist at fertileground-nutrition.com

What the experts say

Read reviews from experts who work in partnership with OvuSense to provide you with the best care throughout your journey to pregnancy.

Dr Irfana Koita
Consultant at IVF Matters

“I recommend OvuSense to my patients as a key part of cycle monitoring whether trying to conceive naturally or undergoing treatment. Knowing your unique cycle characteristics is vital when trying to get pregnant.

As a regulated medical device OvuSense has been evaluated in two independent clinical trials and over 10,000 cycles of use, so I am confident OvuSense will give you vital information on your journey to a successful pregnancy.”

Dr Koita is a member of The Royal College of Obstetricians and Gynaecologists (MRCOG), UK and has achieved a Masters in Healthcare Leadership from Cornell University, USA. She has over 10 years of clinical experience in the field of assisted reproduction and is the director of IVF Matters, the UK’s 1st online fertility clinic. ivfmatters.co.uk
Kate Davies
Fertility Nurse and Coach at Your Fertility Journey

“I recommend OvuSense to all my patients. OvuSense empowers women to understand their cycle and identify ovulation. At last, women can find out exactly when they ovulate to optimize conception.”

Kate is a registered Nurse specialist and has over 20 years’ experience in fertility and Women’s Health. Having completed a degree in Sexual Health at Greenwich University in the UK in 2008, Kate has also completed her training as a Fertility Coach. yourfertilityjourney.com
OvuSense compared to OPKs and BBT
OvuSense compared with Fertility Apps
Carys Morgan
Acupuncturist, motivational writer and speaker

“Trained at The College of Integrated Chinese Medicine in Reading, Berkshire, Carys graduated in 2001. Carys has studied both Traditional Chinese Medicine and Five Element Acupuncture. She has since undertaken post graduate studies in Obstetrics and Gynaecology, Acupuncture for Fertility, Pregnancy and Childbirth and Nutrition and now specialises in Women’s Health.

Both passionate and enthusiastic about all that Acupuncture can offer, Carys is committed to working alongside Western Medicine to offer a safe, drug free and complementary approach to healthcare. Carys currently works at Harley Street Fertility Clinic and Harley Street Healthcare Clinic.”

Carys recommends OvuSense to her patients when undergoing fertility treatment with her. carysmorgan.co.uk
Dr Nicola Harrison
Private General Practitioner

“As a GP, I see many women who are struggling to conceive and wondering if and when they ovulate. OvuSense offers accurate clinical information about their cycle placing the patient in control of her fertility.”

Dr Nicola Harrison is an experienced London GP in both the NHS and privately for the last 10 years having graduated from Guy’s and St Thomas’ Medical School, London in 2003. She is the Medical Director for her Harley Street private practice – ROC Private Clinic. She has a special interest in women’s health, sexual health, allergy, child health and preventative healthcare. She used to be a Health Consultant for LOOK magazine writing weekly articles, has been guest writer for Mother and Baby Magazine, and is currently Resident GP for Annabel Karmel’s Parenting website.
Amy Medling
Certified Health Coach and founder of PCOS Diva

“I’ve seen many excellent examples of OvuSense helping women who have PCOS to take back control of their cycles. In addition to predicting ovulation with 99% accuracy, OvuSense is the only product on the market right now that will tell you if you haven’t ovulated in a given cycle (which is extremely important for PCOS with irregular cycles). It can also tell you the length of your luteal phase.”

Amy is a certified Health Coach and founder of PCOS Diva. It’s Amy’s life’s work to help women use their PCOS diagnosis to transform their lives and fulfill their goals. pcosdiva.co.uk
Angela Heap
Fertility Nutritionist at fertileground-nutrition.com

“I’m a nutritionist who specializes in fertility. I’ve been looking for a fertility monitor that looks at core temps for my clients for a long time and so excited to have found OvuSense at the fertility show 2014. I’ve been using OvuSense personally and can thoroughly recommend it! I’ve just recently had progesterone blood tests back to confirm what my monitor said over a week ago that ovulation took place. Can’t recommend this monitor enough along with other changes like lifestyle diet and supplements when trying to conceive!”

Angela is a trained fertility nutritionist with qualifications in Nutritional Therapy from the College of Naturopathic Medicine. As part of the Fertile Food Programme, Angela applies a mixture of Naturopathic principles and a functional and scientific approach to food and nutrients. fertileground-nutrition.com

Listen to the fertility experts

Did you know OvuSense has it’s own podcast, The Ovusense Podcast? Click the link below to listen, or search ‘The OvuSense Podcast’ wherever you normally get your podcasts.